Efrat Dotan MD (@efratdotan) header
Efrat Dotan MD (@efratdotan) profile picture

Executive Medical Director, Penn Medicine Ann B. Barshingr Cancer Institute. Lancaster General Health

Philadelphia
Joined November 2013
Photo by Efrat Dotan MD (@efratdotan)Photo by Efrat Dotan MD (@efratdotan)Photo by Efrat Dotan MD (@efratdotan)Photo by Efrat Dotan MD (@efratdotan)Photo by Efrat Dotan MD (@efratdotan)Photo by Efrat Dotan MD (@efratdotan)Photo by Efrat Dotan MD (@efratdotan)Photo by Efrat Dotan MD (@efratdotan)Photo by Efrat Dotan MD (@efratdotan)Photo by Efrat Dotan MD (@efratdotan)
Efrat Dotan MD retweeted
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: bit.ly/4BvJVrG
2
17
16
70
15,948
"Ultimately, time is the most precious thing any person has—never more so than after a cancer diagnosis—and protecting how it is spent is a goal worth our shared effort." Our piece - The commodification of Time Toxicity In Oncology ascopubs.org/doi/10.1200/JCO…
8
2
21
4,226
Standing ovation for Daraxonrasib data! Amazing advancements for pancreatic cancer patients. #ASCO26.
7
273
#ClinicalTrial EA6244, led by @YanaNajjarMD of @UPMCHillmanCC, is testing a less invasive treatment approach for older adults with early-stage #melanoma. Learn more: bit.ly/ea6244-study
1
1
142
Efrat Dotan MD retweeted
A new study reveals FOLFIRINOX is feasible for select elderly patients w/ pancreatic cancer. In an accompanying editorial, @ramsedhom & @efratdotan emphasized the study adds critical insights on the “tension between efficacy and tolerability.” @TargetedOnc spr.ly/6017hDOd9
2
4
230
Efrat Dotan MD retweeted
📌NALIRIFOX vs Gem-nabpaclitaxel in >70 y patients subgroup analysis of NAPOLI 3 @ESMO_Open @myESMO ✅Benefit sustained ✅No signal for increased toxicity 👉esmoopen.com/article/S2059-7… #cancer #omcology #MedX #pancreatic @OncoAlert @realbowtiedoc
23
60
3,553
Imagine 4 new anticancer drugs Pallituzumab, Geriatriximab, Symptomab, & Exercizumab hit the market. They should dominate the plenary sessions at ASCO & command billion-dollar revenue. But they don't because they're nonpharmacologic & shame on us. Read our opinion piece in @JCO_ASCO ascopubs.org/doi/full/10.120…
6
37
9
108
23,811
Replying to @efratdotan
@efratdotan & I in @JCOOP_ASCO on pancreatic cancer in older adults ascopubs.org/doi/10.1200/OP-… 1. PDAC needs a systems approach of evaluating fitness for older adults. We make the analogy that Edison's light bulb is useless without durable filaments, sockets, electric grids
2
8
18
1,252
Do you have advanced non-small cell #LungCancer and are age 70 or older? If so, you may be able to participate in this study of a new treatment approach. Learn more: bit.ly/ea5221-achieve cc: @BalazsHalmosMD, @efratdotan, @CPresGeriOncMD
2
3
376
Efrat Dotan MD retweeted
Voting for ASCO Election closes Mon, Dec 8 @ 3PM ET! I am honored to be running as one of the candidates for the Nominating Committee. Visit asco.org/election to learn more and vote!
2
18
9
47
10,464
A new study shows that elevated early-onset cancer incidence is accompanied by similar increases in older adults. The increase is “not restricted to young adults but affects all generations," noted @LGHealth’s @efratdotan in an editorial. spr.ly/6019Ah0HL
1
2
232
Efrat Dotan MD retweeted
Congrats @NVijayvergiaMD on being awarded the 2025 @NANETS1 Distinguished Clinician Award. You’re truly a leader in our field and such a big inspiration for so many like me. Thanks for your phenomenal and impactful work; this is such a well-deserved honor. @PamelaKunzMD @FoxChaseCancer
7
4
2
44
8,726
Do you have advanced non-small cell #LungCancer and are age 70 or older? If so, you may be able to participate in this study of a new treatment approach. Learn more: bit.ly/ea5221-achieve cc: @BalazsHalmosMD, @efratdotan, @CPresGeriOncMD
1
3
212
Congratulations Neena and @FoxChaseCancer ! 👏🏽👏🏽👏🏽@NVijayvergiaMD
Time to celebrate 🤩 @NVijayvergiaMD! She’s the new #GI Section Leader of @FoxChaseCancer 👏👏. I am sure she’s going do a FANTASTIC job!!!! I am SO proud of her!!!! CONGRATULATIONS 🎉🍾🎈🎊!!!! @ChrisCannMD #cancer #cancerresearch @eaonc
1
1
12
1,085
Such a well deserved standing ovation for Chris Booth and the Challenge trial. These data are quite powerful. Much stronger evidence than what we saw in plenaries today. #ASCO25
5
64
10
246
30,694
New standard of care for stage III, improved DFS with the addition of atezolizumab to FOLfOX. Yet, many questions remain regarding the length of therapy and possible use of immunotherapy alone. #ASCO2025
4
20
874
Inspiring presentation by @HKlepinMD on her journey in geriatric oncology. Congratulations for well deserved winner of the geriatric oncology ASCO award. #ASCO2025
1
2
12
446